We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Frost & Sullivan Confers Enabling Technology Award on Peptisyntha


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Frost & Sullivan Confers Enabling Technology Award on Peptisyntha"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Continued research of potentially cost-effective and novel applications of technologies for peptide production is indicative of Peptisyntha's ever-expanding competencies.

"Peptisyntha is one of the few suppliers that can provide high quality, cGMP-compliant therapeutic peptide products and services at competitive prices to customers in the pharmaceutical and biotechnology industries," notes Frost & Sullivan Research Analyst Aiswariya Chidambaram. "A versatile and innovative technology portfolio has enabled Peptisyntha to implement various synthesis processes, customised to suit customer-specific needs."

Key technologies include Silylation technology used in peptide synthesis, Tetraphenylborate (TBP) technology for the synthesis of Arginine-rich peptides, world class manufacturing processes of non-natural amino acid building blocks and others such as the use of Phenyl-oxy-carbonyl-protection (Phoc-AA) of amino acids/ peptides in the coupling reaction.

Silylation technology enables working with non-protected amino acids and peptide fragments, thereby reducing the need for protection and de-protection steps. This, in turn, translates into saving of labour, resources and cost as well as optimal equipment utilisation.

Tetraphenylborate technology aids the cost-effective manufacturing of Arginine- and Lysine-rich peptides, such as anti-microbial peptides and cell penetrating peptides. The LHRH or GnRH peptides produced using Peptisyntha's exclusive TPB technology, are a well-known class of therapeutic peptides manufactured cost effectively by Peptisyntha. These peptides find use in several therapeutic domains, including the treatment of hormone-dependent cancers and fertility control.

"Peptisyntha's proprietary technologies enable cost-effective production of APIs by increasing yield and purity, reducing the number of chemical steps, avoiding racemisation" remarks Aiswariya Chidambaram. "The technologies offered by Peptisyntha are highly flexible, as they are not limited to one typical product line, but can be used for a wide range of peptide APIs spanning all therapeutic areas."

Currently, the company is working on two projects based on advanced peptide biomaterials using peptide self-assembling properties. Firstly, peptide hydrogels for cell culture and, secondly, peptide-based biomaterials for sustained/controlled drug release.

"With peptide-dedicated laboratories, kilo labs, pilot and commercial scale manufacturing units, Peptisyntha offers the advantage of a single point of contact for R&D, process development and production of peptide APIs," concludes Aiswariya Chidambaram. "The company has excelled in delivering its technology to market participants by ensuring optimal peptide purity, quality yield, development timeline and affordable pricing" Said Dr. Johan Devenyns, Managing Director of Solvay Peptides. "This Award is the result of more than two decades of efforts and innovation to contribute to our customers' success around the globe. Performance and expertise combined with innovative solutions lead to this competitive advantage our customers are benefitting from" added Dr. Mimoun Ayoub, Vice President Global Business & Strategic Developments.

The Enabling Technology Award is presented to the company that has demonstrated success in enabling the creation of new products, enhancing current products and enabling new applications. Other criteria according to which the company was selected as the award recipient include potential for market acceptance and breadth of access to technology.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

Advertisement